Azithromycin/hydroxychloroquine - Iterum Therapeutics
Alternative Names: Azithromycin plus hydroxychloroquine; Azithromycin/hydroxychloroquineLatest Information Update: 09 Sep 2021
At a glance
- Originator Iterum Therapeutics
- Class Anti-inflammatories; Antibacterials; Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Macrolides; Quinolines; Small molecules
- Mechanism of Action Autophagy inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory tract infections
Most Recent Events
- 09 Sep 2021 Chemical structure information added
- 07 Sep 2021 Iterum Therapeutics plans a phase III trial for Respiratory tract infections in USA (PO) in October 2021 (NCT05026801)
- 07 Sep 2021 Iterum Therapeutics withdraws prior to initiation a phase III trial for Respiratory tract infections in USA (PO) in August 2021 due to inadequate support for the study(NCT05026801)